FINWIRES · TerminalLIVE
FINWIRES

NSE:GLENMARK

5 stories mentioning NSE:GLENMARK

Every FINWIRES story that references NSE:GLENMARK, newest first.

Asia

Glenmark Pharmaceuticals Unit Launches Acne Treatment Winlevi in European Markets

Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296) said its wholly owned subsidiary Glenmark Specialty has launched acne treatment Winlevi across several European markets, according to a Thursday filing on Indian exchanges.The company has started direct commercialization of the product in markets including Spain, the Nordic region and Central and Eastern Europe, while the launch in Portugal is being carried out through a strategic partner, the filing said.The European Commission granted approval for Winlevi to Cassiopea, a subsidiary of Cosmo Pharmaceuticals, in October 2025, to treat acne vulgaris in adults and adolescents, according to the filing.

BOM:532296NSE:GLENMARK
Asia

Indian Equities Slip on Friday After RBI Flags Higher Inflation, Lower Growth Outlook

Indian benchmark indices ended modestly lower on Friday, giving up early gains as investors assessed the Reserve Bank of India's latest economic projections and booked profits following the monetary policy announcement.The BSE Sensex fell 116.67 points, or 0.2%, to close at 74,243.34, while the NSE Nifty 50 declined 49.85 points, or 0.2%, to settle at 23,366.70.Markets traded in a volatile range after the RBI left the repo rate unchanged at 5.25%, in line with expectations. However, the central bank highlighted risks stemming from the prolonged West Asia conflict, elevated energy prices and global supply-chain disruptions.Investor sentiment was weighed down by the RBI's revised forecasts, which raised its inflation estimate for 2026-27 to 5.1% from 4.6% and lowered its GDP growth projection to 6.6% from 6.9%. The central bank cited the impact of higher global energy prices on domestic fuel costs and broader economic activity.In corporate developments, Bharat Heavy Electricals (NSE:BHEL, BOM:500103) secured an engineering, procurement and construction contract worth 210 billion rupees from Meja Urja Nigam for the 3x800 MW Meja Supercritical Thermal Power Project Stage-II in Uttar Pradesh.Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296) said its U.S. subsidiary launched Lacosamide Injection USP, a generic version of Vimpat Injection, for the treatment of certain seizure disorders.

^BSENifty 50BOM:500103BOM:532296NSE:BHELNSE:GLENMARK
Asia

Glenmark Pharmaceuticals Launches Generic Seizure Drug in US

Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296) said its U.S. arm has launched Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL) single-dose vials, according to a Friday filing on Indian bourses.The product is a generic version of Vimpat Injection, 200 mg/20 mL, marketed by UCB, the filing said.Lacosamide injection is indicated for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures.Shares of the company fell nearly 1% in recent trade.

BOM:532296NSE:GLENMARK
Asia

Glenmark Pharmaceuticals' Profit Soars in Fiscal Q4

Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296) posted a consolidated profit attributable to owners of 3.01 billion Indian rupees in the fiscal fourth quarter, up from 46.5 million rupees a year earlier, according to a Friday filing by the pharmaceutical manufacturer.Earnings per share for the quarter ended March 31 increased to 10.68 rupees from 0.16 rupees a year earlier.Revenue from operations rose to 37.7 billion rupees from 32.6 billion rupees in the prior-year period.

BOM:532296NSE:GLENMARK
Asia

Glenmark Pharmaceuticals Launches Vancomycin Hydrochloride for Injection in US

Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296) has launched Vancomycin Hydrochloride for injection, 500 mg/vial and 1 g/vial in the US, according to a Monday filing to the Indian stock exchanges.The drug is bioequivalent and therapeutically equivalent to Fresenius Kabi's reference-listed drug Vancomycin Hydrochloride for injection.According to IQVIA estimates, Vancomycin Hydrochloride for injection had annual sales of around $37.9 million for the 12 months ended March.

BOM:532296NSE:GLENMARK